Page last updated: 2024-12-07

ecgonine methyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ecgonine methyl ester: major metabolite of cocaine; RN given refers to parent cpd (1R-(exo,exo))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ecgonine methyl ester : The O-debenzoyl analogue of cocaine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID104904
CHEMBL ID1232472
CHEBI ID31529
SCHEMBL ID328854
MeSH IDM0106374

Synonyms (30)

Synonym
CHEBI:31529 ,
(1r,2r,3s,5s)-2-(methoxycarbonyl)tropan-3-ol
CHEMBL1232472 ,
3-hydroxy-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid methyl ester
7143-09-1
ecgonine methyl ester
8-azabicyclo[3.2.1]octane-2-carboxylic acid, 3-hydroxy-8-methyl-, methyl ester, [1r-(exo,exo)]-
methylecgonine
8-azabicyclo[3.2.1]octane-2-carboxylic acid, 3-hydroxy-8-methyl-, methyl ester, (1r,2r,3s,5s)-
8-azabicyclo(3.2.1)octane-2-carboxylic acid, 3-hydroxy-8-methyl-, methyl ester, (1r,2r,3s,5s)-
8-azabicyclo(3.2.1)octane-2-carboxylic acid, 3-hydroxy-8-methyl-, methyl ester, (1r-(exo,exo))-
DB04688
methyl (1r,2r,3s,5s)-3-hydroxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
AKOS006274769
bdbm50417947
y35fjb3qbj ,
unii-y35fjb3qbj
EPITOPE ID:161060
ecgonine methylester
SCHEMBL328854
methylecognine
methylecgonine [who-dd]
ecgonine methyl ester [mi]
2beta-carbomethoxy-3beta-hydroxytropane
QIQNNBXHAYSQRY-UYXSQOIJSA-N
ecgoninemethylester
ecgonine methyl ester 1.0 mg/ml in acetonitrile
ecgonine methyl ester (eme)
DTXSID00891435
Q27095434

Research Excerpts

Toxicity

benzoylecgonine and ecgonine methyl ester are not as toxic as cocaine, norcocaine, or cocaethylene when administered intravenously to pharmacologically naive rats.

ExcerptReferenceRelevance
"Cocaine, norcocaine, cocaethylene, benzoylecgonine, and ecgonine methyl ester were infused intravenously to produce sequential behavioral alterations and central nervous system and cardiovascular toxic effects."( The comparative toxicity of cocaine and its metabolites in conscious rats.
Cooper, TB; Iso, A; Morishima, HO; Whittington, RA, 1999
)
0.55
"The dose of norcocaine necessary to produce toxic effects was smaller than that of cocaine and cocaethylene."( The comparative toxicity of cocaine and its metabolites in conscious rats.
Cooper, TB; Iso, A; Morishima, HO; Whittington, RA, 1999
)
0.3
"These results indicate that benzoylecgonine and ecgonine methyl ester are not as toxic as cocaine, norcocaine, or cocaethylene when administered intravenously to pharmacologically naive rats."( The comparative toxicity of cocaine and its metabolites in conscious rats.
Cooper, TB; Iso, A; Morishima, HO; Whittington, RA, 1999
)
0.56
" However, to date the knowledge on their adverse effects to non-target organisms is inadequate."( Adverse effects induced by ecgonine methyl ester to the zebra mussel: a comparison with the benzoylecgonine.
Binelli, A; Parolini, M, 2013
)
0.69
" These observations confirm that the drug metabolites generated after CocH gene transfer therapy are safe even after a dose of cocaine that would ordinarily be lethal."( Reward and Toxicity of Cocaine Metabolites Generated by Cocaine Hydrolase.
Brimijoin, S; Gao, Y; Geng, L; Miller, JD; Murthy, V; Reyes, S; Zhang, B, 2015
)
0.42
" Thus, the present study was aimed at investigating the potential adverse effects induced by the exposure to environmental concentrations (0."( Environmental concentrations of cocaine and its main metabolites modulated antioxidant response and caused cyto-genotoxic effects in zebrafish embryo cells.
Binelli, A; Calvagno, M; Del Giacco, L; Della Torre, C; Ghilardi, A; Magni, S; Parolini, M; Prosperi, L, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic profile of these congeners was not dose dependent when the two doses administered were compared."( Cocaine, norcocaine, ecgonine methylester and benzoylecgonine pharmacokinetics in the rat.
Diaz, J; Jamdar, S; Mets, B; Soo, E, 1999
)
0.3
" There were few differences in the pharmacokinetic profile of cocaine across the menstrual cycle."( Pharmacokinetics of intravenous cocaine across the menstrual cycle in rhesus monkeys.
Evans, SM; Foltin, RW, 2004
)
0.32
" The results demonstrated that the plasma elimination half-life of cocaine is nearly three times longer in males versus females."( Gender differences in cocaine pharmacokinetics in CF-1 mice.
Abdel-Rahman, MS; Turkall, R; Visalli, T, 2005
)
0.33
" These findings suggest that while progesterone has an impact on locomotor behavior, pharmacokinetic effects may have a limited role in mediating behavioral responses to cocaine."( Estrogen and progesterone affect cocaine pharmacokinetics in female rats.
Akhavan, A; Festa, ED; Foltz, R; Lamm, L; Lin, SN; Niyomchai, T; QuiƱones-Jenab, V, 2006
)
0.33
"No controlled cocaine administration data describe cocaine and metabolite disposition in oral fluid (OF) collected with commercially-available collection devices, OF-plasma ratios, and pharmacodynamic relationships with plasma and OF cocaine and metabolite concentrations."( Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration.
Concheiro, M; Ellefsen, KN; Gorelick, DA; Huestis, MA; Pirard, S, 2016
)
0.43
" Peak subjective effects ("Rush," "Good drug effect" and "Bad drug effect") occurred prior to peak OF cocaine concentration, whereas observed peak plasma concentrations and subjective measures occurred simultaneously, most likely due to significantly earlier plasma Tmax compared to OF Tmax."( Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration.
Concheiro, M; Ellefsen, KN; Gorelick, DA; Huestis, MA; Pirard, S, 2016
)
0.43
"OF offers advantages as an alternative matrix to blood and plasma for identifying cocaine intake, defining pharmacokinetic parameters at different confirmation cutoffs, and aiding different drug testing programs to best achieve their monitoring goals."( Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration.
Concheiro, M; Ellefsen, KN; Gorelick, DA; Huestis, MA; Pirard, S, 2016
)
0.43
"The pharmacokinetic profile of oral cocaine has not been fully characterized and prospective data on oral bioavailability are limited."( Bioavailability and Pharmacokinetics of Oral Cocaine in Humans.
Coe, MA; Cone, EJ; Jufer Phipps, RA; Walsh, SL, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
"The pharmacokinetic profile of oral cocaine has not been fully characterized and prospective data on oral bioavailability are limited."( Bioavailability and Pharmacokinetics of Oral Cocaine in Humans.
Coe, MA; Cone, EJ; Jufer Phipps, RA; Walsh, SL, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" The range of the dose-response curve is 0-400 ng ml-1 benzoylecgonine."( Radioimmunoassay of benzoylecgonine in samples of forensic interest.
Robinson, K; Smith, RN, 1984
)
0.27
" Fourteen healthy inpatient participants (six males) with current histories of cocaine use were administered two oral doses (100 and 200 mg) and one intravenous (IV) dose (40 mg) of cocaine during three separate dosing sessions."( Bioavailability and Pharmacokinetics of Oral Cocaine in Humans.
Coe, MA; Cone, EJ; Jufer Phipps, RA; Walsh, SL, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
central nervous system depressantA loosely defined group of drugs that tend to reduce the activity of the central nervous system.
peripheral nervous system drugA drug that acts principally at one or more sites within the peripheral neuroeffector systems, the autonomic system, and motor nerve-skeletal system.
analgesicAn agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
opioid analgesicA narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
tropane alkaloid
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)416.86900.00091.901410.0000AID576612
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (130)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (5.38)18.7374
1990's46 (35.38)18.2507
2000's34 (26.15)29.6817
2010's38 (29.23)24.3611
2020's5 (3.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.99 (24.57)
Research Supply Index5.06 (2.92)
Research Growth Index5.28 (4.65)
Search Engine Demand Index61.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.30%)5.53%
Reviews1 (0.65%)6.00%
Case Studies5 (3.25%)4.05%
Observational0 (0.00%)0.25%
Other146 (94.81%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]